Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 31, 2023

Olaparib Plus Bevacizumab as First-Line Maintenance for Advanced Ovarian Cancer



Additional Info

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
ESMO Open 2023 May 19;[EPub Ahead of Print], I Ray-Coquard, A Leary, S Pignata, C Cropet, A González-Martin, C Marth, S Nagao, I Vergote, N Colombo, J Mäenpää, F Selle, J Sehouli, D Lorusso, EMG Alia, G Bogner, H Yoshida, C Lefeuvre-Plesse, P Buderath, AM Mosconi, A Lortholary, A Burges, J Medioni, A El-Balat, M Rodrigues, TW Park-Simon, C Dubot, D Denschlag, B You, E Pujade-Lauraine, P Harter

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading